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Indeterminate cell histiocytosis (ICH) is a rare proliferative disorder, in which the predominant cells share morphologic and
immunophenotypic features from both Langerhans and non-Langerhans cell histiocytosis. We describe a 62-year-old man
presenting a 2-month history of ﬁrm nodular lesions on the upper lip. Histopathology, immunohistochemical, and ultrastructural
analysis showed typical ﬁndings of ICH. The patient was treated with thalidomide and almost complete regression of the lesions
was reached within 7 months. Nevertheless, one month after remission, he developed an acute myeloid leukemia of the subtype
monocytic leukemia (M5). The patient’s condition rapidly worsened and he died due to a respiratory failure four weeks later. We
present this case because apart of being rare it joins the eﬀectiveness of thalidomide and the association with an acute monocytic
leukemia. A review of the literature is made.
1.Introduction
Indeterminate cell histiocytosis (ICH) is a rare proliferative
disorder, in which the predominant cells share morphologic
and immunophenotypic features from both Langerhans and
non-Langerhans cell histiocytosis. Clinically, most patients
present multiple asymptomatic papulonodules with a colour
variation from pink to brownish, covered by intact skin.
Solitary lesions may also occur like soft nodules mainly on
the trunk and arms. ICH lesions are usually restricted to the
skin [1]. The major part of these cases have an indolent and
benign course, not requiring aggressive treatment.
2.CaseReport
A 62-year-old Caucasian man presented a 2-month history
of ﬁrm nodular lesions on the upper lip (Figure 1). These
lesions were isolated and conﬂuent; some of them were cov-
ered by hemorrhagic crusts. The mucous membranes were
not involved and the lesions were painless and nonpruritic.
Hewasnottakinganymedication.Skinbiopsywastakenand
sentforhistopathologyandcultures.Histopathologyshowed
ad i ﬀuse, monomorphous, nonepidermotropic inﬁltrate of
large “histiocytic” cells with eosinophilic cytoplasm and
irregularly shaped nuclei throughout the entire dermis.
These cells were mixed with lymphocytes, plasma cells, and
eosinophils (Figures 2(a) and 2(b)). Immunohistochemical
examination revealed that the predominant cells coexpressed
CD1a (Figure 3(a)), CD68 markers (Figure 3(b)), and
S100 protein (Figure 3(c)). They were negative for CD3,
CD4, CD8, CD20, CD30, CD79a, and FXIIIa markers. The
ultrastructural analysis conﬁrmed the dendritic morphology
of the inﬁltrating cells and the absence of Birbeck granules.
Culture for bacteria, mycobacteria, and fungi was negative.
The diagnosis of ICH was made. Clinical staging, includ-
ing complete hematologic examination with bone marrow
biopsy, chest X-ray, and chest, abdominal and pelvic CT
were normal. Thalidomide 200mg daily was initiated after
neurological examination. After 2 months of treatment,
the lesions underwent gradual regression and the dose of
thalidomide was reduced to 100mg/day. Almost complete
remission of the lesions was observed by the seventh month2 Dermatology Research and Practice
Figure 1: Nodular lesions located on the upper lip.
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Figure 2: (a) Histopathology revealed a diﬀuse, monomorphous,
nonepidermotropic inﬁltrate of large epithelioid cells throughout
the entire dermis. (stain type—Hematoxylin and eosin; origi-
nal magniﬁcation: ×100). (b) Histopathology revealed a diﬀuse,
monomorphous, nonepidermotropic inﬁltrate of large epithelioid
cells throughout the entire dermis. (stain type—Hematoxylin and
eosin; original magniﬁcation: ×400).
(Figure 4). No adverse eﬀects from treatment were observed
on the clinical and electrophysiological examinations. How-
ever, at this time, the laboratory ﬁndings showed hyper-
leucocytosis (white blood count 72,9 × 109/L) with 67%
blasts, anemia (hemoglobin 6,1g/dL), thrombocytopenia
(platelet count 34 × 109/L), hyperuricemia (serum acid uric
12,4mg/dL, normal), high levels of lactate dehydrogenase
(1087U/L, normal), and β2-microglobulin (2610ng/mL,
normal). The bone marrow aspirate was hypercellular with
extensive inﬁltrate by the blasts. The blasts were positive for
α-naphthylacetate esterase, myeloperoxidase, and Periodic
Acid-Schiﬀ (PAS). Flow cytometry analysis revealed a blast
population with monocytic diﬀerentiation expressing CD-
11B, CD14, CD15, CD33, CD36, CD45, CD56, CD64,
and HLA-DR, but lacking CD34 expression. These ﬁndings
support a diagnosis of an acute monocytic leukemia by the
World Health Organization (WHO). Cytogenetic analysis
showed two abnormal clones on the chromosomes 7 and
18. Treatment with hydroxyurea had been initiated; however
patient’s condition deteriorated and he died 1 month later
due to a respiratory failure.
3. Discussion
Histiocytoses are a heterogeneous group of disorders charac-
terized by the proliferation and accumulation of cells of the
mononuclear-macrophage system and the dendritic cells [2].
All these cells derive from neutrophil/macrophage lineage
progenitor cells in bone marrow [3, 4]. There are reported
in the literature diﬀerent opinions trying to classify these
challenging but poorly understood disorders.
In what concerns to the indeterminate cells’ origin and
the ICH there is still a lot of controversy. Indeterminate cells
aredeﬁnedtobecloselyrelatedtoLangerhanscells,histologi-
callyandimmunocytochemically,butdonotcontainBirbeck
granules. Some authors have reported that indeterminate
cells may represent precursors of Langerhans cells which
acquire Birbeck granules as they transit from dermal to
epidermal sites, possibly the result of the interaction between
their cell receptors and epidermis-speciﬁc ligands [1, 2, 5].
Otherssuggestthatindeterminatecellsrepresentmembersof
thedermal/epidermaldendriticcellsystemthatmigratefrom
the skin to the regional lymph nodes [1, 2, 5]. Hence ICH
seems to be a disorder of proliferating indeterminate cells
which have been locally arrested before they can leave the
skin travelling as veiled cells via the lymphatics to the T-cell-
dependent paracortical areas of the regional lymph nodes
[1, 2, 5].
More recently, it has been suggested that what today is
described as ICH could be a variant of non-Langerhans’
cell histiocytosis (NLCH) rather than an overlap between
Langerhans cell histiocytosis (LCH) and NLCH [2]. In
fact ICH shows mainly features of NLCH except for the
consistent expression of S-100 protein. This is not totally
surprising because aberrant S-100 protein has been reported
before [2]. Other authors believe that there are disorders
of Langerhans cells and macrophages; both diﬀer according
to the time cycle of the lesions. Late stages of LCH may
completely lose Langerhans cells markers and then consist
mainly of xanthomatized macrophages. On the other hand,
macrophage disorders have a polymorphous presentation
which also includes their immunoproﬁle.
Nowadays it is not clear that ICH is a separate entity
or if represents various macrophage disorders identiﬁed at
diﬀerent periods in the inﬂammatory response.
Proliferative disorders of indeterminate cells have a wide
spectrum of clinical severity and a variable clinical course.Dermatology Research and Practice 3
(a) (b)
(c)
Figure 3: Immunohistochemical examination showed positivity for CD1a (a), CD68 (b), and S100 protein (c).
Figure 4:Regressionofthelesionsafter7monthsoftreatmentwith
thalidomide.
The majority of cases have a benign clinical behaviour
and self-healing skin lesions that completely or partially
regress spontaneously, requiring no aggressive treatments
[5, 6]. Chemotherapy is necessary for aggressive cutaneous
ICH, deﬁned as ICH involving over 50% of the body
surface and lasting at least 6 months with no tendency
to spontaneous resolution and with new crops of lesions
continuing to appear [6]. In our case in spite of localized
lesions without visceral involvement, it was a disﬁgurating
cutaneous lesion and we have decided to treat the patient
with thalidomide 200mg/day, with almost complete regres-
sion of the lesions after 7 months. Our decision was based
on the predominantly cutaneous pharmacological eﬀect,
immunomodulatory and anti-inﬂammatory properties of
thisdrug.Ithasalsobeenshownthatthalidomidemodulated
the function properties of monocyte-derived dendritic cells
[7].
An association between ICH and malignancies has been
described in four patients: twice with low grade B-cell
lymphomas [2], once with mast cell leukemia [8], and
another with myelomonocitic leukemia [1]. Our patient
presented a monocytic leukemia 7 months after the onset of
the skin lesions.
While antineoplastic drugs are used, such as cyclophos-
phamide, vinblastine, etoposide, and 2-chlorodeoxyadeno-
sine, to treat aggressive diﬀuse forms of ICH, the possibility
of this treatment being related on the etiology of oncohema-
tological disorders cannot be excluded [6]. It does not occur
in our case because it was used thalidomide, with proven
eﬀectiveness on multiple myeloma and myelodysplastic
syndrome [9].
The biological basis of the association between an
ICH and leukemia remains unknown. It is known that
macrophages are derived from circulating monocytes and
thus share a common bone-marrow progenitor cell, the
neutrophil/macrophage colony-forming unit. So, in what4 Dermatology Research and Practice
concerns to our case, the association between indeterminate
cell histiocytosis and monocytic leukemia was probably
greater than that by chance alone. We present this case
because apart of being rare it joins the eﬀectiveness of
thalidomide and the association with an acute monocytic
leukemia.
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